Efficacy and tolerability of quetiapine in patients with mental retardation and behavioural disorders;Efficacia e tollerabilità della quetiapina in pazienti con ritardo mentale e disturbi comportamentali

Nuova Rivista di Neurologia

Volumn 13, Issue 4, 2003, Pages 122-125

  La Malfa, Giampaolo ^a,b   Bertelli, Marco ^a   Lassi, Stefano ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Clinica Psichiatrica   (Italy)

Author keywords

Atypical antipsychotic; Behavioural disorders; Mental retardation; Quetiapine

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; QUETIAPINE;

ADULT; ARTICLE; BEHAVIOR; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVALUATION; FEMALE; HUMAN; INCIDENCE; INCREASED APPETITE; INSTITUTIONAL CARE; LONG TERM CARE; MALE; MENTAL DEFICIENCY; PATIENT; SCORING SYSTEM; SEDATION; SIDE EFFECT; SKILL; SYMPTOM; WEIGHT GAIN;

EID: 0344010038     PISSN: 1122035X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Worrel JA, Marken PA, Beckham SE, et al. Athipical antipsychotic agents: A critical review. Am J Health Syst Pharm 2000; 57: 238-55.
2. Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000; 18: 106-24.
3. McGrath J, Emmerson WB. Treatment of schizophrenia. Br Med J 1999; 519: 1045-8.
4. Horacek J. Novel antipsychotics and extrapyramidal side effects. Theory and reality. Pharmacopsychiatry 2000; 33 (Suppl.1): 34-42.
5. Nasrallah HA, Tandon R. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. J Clin Psychiatry 2002; 63 (Suppl 13): 12-20.
6. Goldstein JM. Preclinical profile of Seroquel (quetiapine): an atipical antipsychotic with clozapine-like pharmacology. In: Holliday SG, Ancill RJ, McEvan GW. Eds. Schizophrenia: Breaking Down the Barriers. Wiley, Chichester 1996; 177-208.
7. Kecks N, Mazumdar P, Steele K. The new antipsychotics. How much better are they? Aust Fam Physician 2000; 29: 445-50.
8. Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 2002; 63 (Suppl 13): 32-8.
9. Fredericks DW, Williams WL. New definition of mental retardation for the America Association of Mental Retardation. Image J Nurs Sch 1998; 30: 53-6.
10. American Psychiatric Association. Manuale diagnostico e statistico dei disturbi mentali, IV Edizione. Masson Italia, Milano, 1995.
11. Wing L. The MRC handicaps behaviour and skill (HBS) schedule. Acta Psychiatr Scand 1980; 62 (suppl. 285): 241-7.
12. Bech P. Rating Scales for Psychopathology. Health Status and Quality of Life. Springer-Werlag, Berlin, 1993.
13. Lund J. The prevalence of psychiatric morbidity in mentally retarded adults. Acta Psychiatr Scand 1985; 72: 563-70.
14. Lund J. Measuring behaviour disorder in mental handicap. Br J Psychiatry 1989; 155: 379-83.
15. Garvey CA, Gross D, Freeman L. Assessing psychotropic medication side effects among children. A reliability study. J Child Adolesc Psychiatr Ment Health Nurs 1991; 4: 127-31.
16. Pastori R, Casali C. Utilizzo della quetiapina (Seroquel) in pazienti con psicosi ed insufficienza mentale. VII Congresso Nazionale della Società Italiana di Psicopatologia SOPSI, Roma 19-23 febbraio 2002. Pisa: Pacini Editore 2002.
17. Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999; 9: 99-107.